Health Catalyst, Inc. (HCAT) - What Are Analysts Saying About This Stock?

Key Points

• Analysts hold a cautious view of Health Catalyst: nine brokerages give the stock a consensus “Hold” rating, with six holds, two buys and one sell. The average 1-year price target is $2.15, though several firms recently lowered their targets.
• Recent insider and institutional activity has been positive: CEO Simeon Kohl purchased 59,000 shares for about $105,610, while institutional investors own approximately 85% of the company’s stock.
• Health Catalyst modestly beat quarterly expectations but remains unprofitable: it reported EPS of $0.04 versus a $0.03 estimate and revenue of $70.49 million, but posted a negative net margin of 90.61%; shares opened at $1.69, near their recent moving averages.

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have earned a consensus recommendation of "Hold" from the nine brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $2.15.

Several equities analysts recently weighed in on the stock. Weiss Ratings raised shares of Health Catalyst from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 28th. Wells Fargo & Company decreased their target price on shares of Health Catalyst from $1.75 to $1.50 and set an "equal weight" rating for the company in a research report on Thursday, August 13th. Citigroup dropped their price target on shares of Health Catalyst from $2.50 to $2.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 11th. Finally, Canaccord Genuity Group restated a "hold" rating and set a $1.80 price target (down from $3.00) on shares of Health Catalyst in a report on Thursday, August 20th.

Insider Transactions at Health Catalyst

In other Health Catalyst news, CEO Simeon Kohl bought 59,000 shares of the stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of $1.79 per share, with a total value of $105,610.00. Following the completion of the transaction, the chief executive officer directly owned 2,856,385 shares of the company's stock, valued at $5,112,929.15. This represents a 2.11% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 19.40% of the company's stock.

Institutional Trading of Health Catalyst

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Palogic Value Management L.P. acquired a new position in shares of Health Catalyst during the 2nd quarter valued at about $9,796,000. BlackRock Inc. acquired a new stake in Health Catalyst in the 2nd quarter worth approximately $3,654,000. Hsbc Holdings PLC acquired a new stake in Health Catalyst in the 2nd quarter worth approximately $809,000. Squarepoint Ops LLC boosted its position in Health Catalyst by 1,214.8% during the second quarter. Squarepoint Ops LLC now owns 400,210 shares of the company's stock worth $796,000 after purchasing an additional 369,772 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Health Catalyst during the first quarter valued at approximately $276,000. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $1.69 on Monday. Health Catalyst has a fifty-two week low of $0.96 and a fifty-two week high of $3.62. The stock's 50-day moving average is $1.72 and its two-hundred day moving average is $1.70. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.70 and a quick ratio of 2.70. The firm has a market cap of $127.19 million, a P/E ratio of -0.46 and a beta of 1.54.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The business had revenue of $70.49 million during the quarter, compared to analyst estimates of $69.09 million. Health Catalyst had a negative return on equity of 1.83% and a negative net margin of 90.61%. Analysts predict that Health Catalyst will post -0.18 earnings per share for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc is a healthcare technology company that provides data and analytics solutions to help healthcare organizations improve clinical outcomes, operational efficiency and financial performance. Its customers include hospitals, health systems, medical groups and other healthcare organizations seeking to integrate and analyze data from across their operations.

The company's offerings are built around its Health Catalyst Data Operating System, a cloud-based platform designed to combine information from electronic health records, financial systems and other sources.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.